Joint, Lung, and Urinary Disease Models Offered at Biocytogen
May 26, 2023
Speaker: Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Inflammatory disease models are important preclinical research tools to study disease pathogenesis and uncover novel treatments. To directly evaluate the efficacy and safety of therapeutic drug candidates targeting these disorders, we can establish disease in wild-type and/or humanized mouse models. In this webinar, […]
Inflammatory Disease Modeling for Preclinical Studies
February 17, 2023
Speaker: Rebecca Soto, Ph.D. Scientist II/Associate Manager Content Marketing, Biocytogen Boston Provided a brief overview on molecular mechanisms driving disease progression. Discussed modeling inflammatory diseases in wild-type and humanized mice, including psoriasis, atopic dermatitis, delayed type hypersensitivity, inflammatory bowel disease and experimental autoimmune encephalomyelitis. Evaluated in vivo efficacy of therapeutic agents in preclinical inflammatory disease […]
Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen
October 4, 2022
Speaker: John Charpentier, Ph.D, Scientific Content Specialist, Biocytogen Boston Defined pharmacokinetics/pharmacodynamics (PK/PD) and useful parameters to measure them Discussed Biocytogen’s platforms suited for antibody PK/PD studies Introduced humanized mouse models useful for evaluation of PK/PD In vivo case studies and examples Q&A session
Preclinical Models to Investigate NK Cell-Targeted Immunotherapies
September 2, 2022
Speaker: Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston Reviewed the mechanisms driving NK cell activity in the context of immuno-oncology, and the types of NK-targeted immunotherapies currently under investigation Introduced experimental models used to evaluate these immunotherapies, including syngeneic models and xenograft models
Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery
June 24, 2022
Speaker: John Charpentier, Ph.D, Business Development Manager, Biocytogen Boston Introduced Biocytogen’s highly immunodeficient B-NDG mouse model Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models Described how B-NDG models recapitulate critical aspects of human biology, making them a powerful tool for biomedical research
Mouse Models to Investigate New Treatments for Inflammatory Disease
January 27, 2022
Speaker: Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston Introduced immune system, cytokines, and autoimmune diseases. Reviewed Modeling Inflammatory Diseases in Wild-Type and Humanized Mice, including multiple Sclerosis/EAE, Rheumatoid Arthritis and Colitis/Inflammatory Bowel Disease. Inflammatory & autoimmune diseases have complex etiologies and mechanisms, but can be modeled in mice. We have established protocols […]
Investigating Inflammatory Disease using Humanized Cytokine Mice
December 2, 2021
Speaker: Clarke Gasper, Ph.D. Senior Business Development Manager, Biocytogen Boston We reviewed the range of cytokines associated with various autoimmune and allergy related diseases. Introduced various humanized cytokine mouse models that can be used in disease modeling. The inflammatory disease models we have developed includes asthma, atopic dermatitis, and psoriasis. Details of some typical readouts […]
Advancing T cell Therapies Using B-hCD3 Mouse Models
November 4, 2021
Biocytogen’s humanized mice are rigorously designed and validated in the following ways to improve translation of CD3-targeting candidates: Expression (mRNA & flow cytometry), Immune cell frequency & maturation profiling and functional validation using reference antibodies whenever available.
Genome Engineering in Accelerating Discovery and Preclinical Applications
September 27, 2021
Use of Biocytogen’s CRISPR-based Extreme Genome Editing technology improves the efficiency of large fragment knock-in by up to 10-20 fold, meaning we can generate targeted cell lines, mouse and rat models in industry-leading timelines with a 98% success rate.
IO Summit Boston: Improve Translation of Humanized Animal Models for Immunotherapy
October 20, 2020
Learn about the new developments in humanized animal models to get ideas on how models can be applied to solve specific translational challenges.
